Company Description
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.
The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
| Country | United States |
| Founded | 1952 |
| IPO Date | Feb 1, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Kristin Peck |
Contact Details
Address: 10 Sylvan Way Parsippany, New Jersey 07054 United States | |
| Phone | 973 822 7000 |
| Website | zoetis.com |
Stock Details
| Ticker Symbol | ZTS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555280 |
| CUSIP Number | 98978V103 |
| ISIN Number | US98978V1035 |
| Employer ID | 46-0696167 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristin C. Peck | Chief Executive Officer and Director |
| Wetteny N. Joseph CPA | Executive Vice President and Chief Financial Officer |
| Roxanne Lagano | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Robert J. Polzer Ph.D. | Executive Vice President and President of Research and Development |
| Jamie Brannan | Executive Vice President and Chief Commercial Officer |
| Keith Sarbaugh | Executive Vice President and Chief Digital and Technology Officer |
| Steven Frank | Vice President of Investor Relations |
| Julie A. Fuller | Executive Vice President, Chief Human Resources Officer and Global Operations |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs and Chief Sustainability Officer |
| Nick Ashton | Executive Vice President and President of Global Manufacturing and Supply |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 3, 2025 | 144 | Filing |
| Jun 2, 2025 | SD | Form - SD |
| May 22, 2025 | 8-K | Current Report |
| May 21, 2025 | 8-K | Current Report |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 9, 2025 | ARS | Filing |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |